对Resorcinyl-imidazole Hsp90抑制剂设计的全面分析

Marius Gedgaudas1, Paulina Kaziukonytė2, Visvaldas Kairys3

  • 1Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio 7, 10257, Vilnius, Lithuania.

概括

新的aryl-resorcinol化合物显示出作为人类热冲击蛋白90 (Hsp90) 抑制剂的前景. 了解Hsp90异型选择性是开发有效癌症治疗的关键.

相关概念视频